[{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Public Offering","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx® (bromelain), establishing a U.S. commercial presence, supporting business development activities, and for general corporate purp...

                          Product Name : NexoBrid

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          July 02, 2023

                          Lead Product(s) : Bromelain

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $27.5 million

                          Deal Type : Public Offering

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx. EscharEx, a concentrate of proteolytic enzymes enriched in bromelain, is an easy to use product candidate, for topical daily appl...

                          Product Name : NexoBrid

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          March 02, 2023

                          Lead Product(s) : Bromelain

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $27.5 million

                          Deal Type : Public Offering

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Study met primary endpoint with patients treated with EscharEx (Bromelain Enriched Proteolytic Enzyme) had statistically significant higher incidence of complete debridement during the 14-day measurement period within up to 8 applications compared to gel...

                          Product Name : EscharEx

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          December 05, 2022

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : EscharEx, a concentrate of proteolytic enzymes enriched in bromelain, for debridement of chronic and other hard-to-heal wounds is a product candidate in advanced stages of development.

                          Product Name : EscharEx

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          December 04, 2022

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The Company intends to use the net proceeds from the Offerings primarily for the development of EscharEx® (bromelain enriched proteolytic enzyme), a scale up of its facilities, and for general corporate purposes.

                          Product Name : EscharEx

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          September 22, 2022

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $30.0 million

                          Deal Type : Private Placement

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The Company intends to use the net proceeds for the development of EscharEx® (bromelain enriched proteolytic enzyme), which has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds and scale up of its faci...

                          Product Name : EscharEx

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          July 10, 2022

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $30.5 million

                          Deal Type : Public Offering

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Preliminary efficacy and safety data from study in patients with venous leg ulcers and diabetic foot ulcers, from a clinical pharmacology study demonstrating EscharEx's fast and effective debriding activity accompanied with reduction in biofilm and bacte...

                          Product Name : EscharEx

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          March 29, 2022

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Patients treated with EscharEx (proteolytic enzymes enriched in bromelain), demonstrated a higher incidence of complete debridement during the 14-day measurement period within up to 8 applications compared to patients treated with gel vehicle.

                          Product Name : EscharEx

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          March 21, 2022

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The study concluded that EscharEx treatment was more effective than the commercially available collagenase agent in removing eschars in this model.

                          Product Name : EscharEx

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          December 21, 2020

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank